Reuters logo
BRIEF-Cerenis receives FDA IND approval to begin studies with CER-209 in NAFLD and NASH
December 16, 2016 / 6:37 AM / a year ago

BRIEF-Cerenis receives FDA IND approval to begin studies with CER-209 in NAFLD and NASH

Dec 16 (Reuters) - Cerenis Therapeutics Holding SA :

* Announced on Thursday that received FDA IND approval to begin studies with CER-209 in NAFLD and NASH

* Investigational New Drug application (IND) for CER-209 includes plans for a Phase I clinical study of its P2Y13 receptor agonist drug candidate (CER-209) in healthy volunteers for clinical investigation of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato-Hepatitis (NASH)

* Says plans to begin enrollment for CER-209 in Q1 2017 Source text: bit.ly/2gQoHjR Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below